Tamura et al. (2012) suggestthat ABCG2 34G>A would be useful in predicting a worsening of skin rash. Lemos et al. (2011) did notfind any significant association between the evaluated ABCG2 polymorphisms andresponse, clinical benefit, time to progression (TTP), or overall survival (OS).Moreover, due to the small sample sizes of the individual studies, there is a needto perform a meta-analysis to combine them and systematically analyze therelationships between ABCG2 gene polymorphism and treatment effectsamong NSCLC patients. The gene discussed is ABCG2; the disease is exanthem.